Premium
The clinical utility of Ki‐67 in assessing tumor biology and aggressiveness in patients with appendiceal carcinoids
Author(s) -
Liu Eric,
Telem Dana A.,
Hwang John,
Warner Richard R.P.,
Dikman Andrew,
Divino Celia M.
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21634
Subject(s) - medicine , ki 67 , proliferative index , proliferation index , gastroenterology , metastasis , retrospective cohort study , correlation , pathology , cancer , immunohistochemistry , geometry , mathematics
Background/Objective To elucidate the correlation of Ki‐67 with tumor biology and survival in appendiceal carcinoid tumors. Method A retrospective chart review conducted on 51 patients with appendiceal carcinoid tumors who underwent surgical intervention from 1991 to 2008. MIB‐1, an antibody of Ki‐67, was used to determine cell proliferation and correlated with clinical and histological parameters. MIB‐1 index was categorized according to the World Health Organization (WHO) classification. Result Of the 51 patients, 32 had tumors <2 cm; 3 >2 cm; and 16 with unspecified tumor size. Increased MIB proliferative index did not significantly correlate with increasing tumor size ( P = 0.426). Twelve patients had metastatic disease on presentation: 9 had MIB‐1 index <2%, 1 had index 2–15% and 2 with index >15%. No significant correlation between MIB index and metastasis was demonstrated ( P = 0.68). Median follow‐up was 40 months (range 10–183 months) with a 51% follow‐up rate. Seven mortalities and three recurrences presented in 26 patients. Assessment of survival demonstrated significantly decreased survival by increasing MIB index. Survival rate by MIB index was as follows: <2% was 97%, 2–15% was 85% and >15% was 67% ( P = 0.02). Conclusion Increased MIB index significantly correlated with decreased survival. No correlation was demonstrated by MIB index and tumor size or presentation with metastatic disease. J. Surg. Oncol. 2010;102:338–341. © 2010 Wiley‐Liss, Inc.